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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the analgesic effects of corticosteroids for the management of cancer-related pain in adults.
B A C K G R O U N D
Description of the condition
Cancer remains the leading cause of death worldwide. Over 12
million new cases are diagnosed each year (Foley 2011). The dis-
ease carries significant morbidity. Pain resulting directly or indi-
rectly from the abnormal growth of malignant cells in normal
tissue is the most common and most feared symptom associated
with cancer (Van den Beuken-van Everdingen 2007). It is esti-
mated that one third of cancer patients in active therapy, and two
thirds of those with advanced disease, experience pain that requires
treatment with analgesic drugs (Foley 2011). Of concern, there is
also considerable evidence that cancer pain is often undertreated
(Foley 2011). While opioids remain the mainstay of treatment for
cancer pain, co-analgesics or adjuvants are often used concurrently
to optimise pain control. Corticosteroids (steroids) are commonly
used in this context.
Description of the intervention
Steroids are essential for maintaining homeostasis and regulating a
wide variety of physiological processes in the human body (Busillo
2013). Therapeutically they are widely prescribed for the treat-
ment of inflammation, auto-immune disorders and malignancies
(Busillo 2013). They are commonly used in the management of
cancer pain.
How the intervention might work
The exact mechanism of action of steroids in relieving pain in
cancer is unknown, but it is probably related to their potent anti-
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inflammatory effect that occurs via a complex interplay between
glucocorticoid receptor-mediated transcriptional regulation and
signal transduction within target tissues (Baschant 2012). Pro-in-
flammatory cytokines have been implicated in a number of dif-
ferent pain states. Steroids may act as anti-inflammatory agents
through the inhibition of these cytokines (Paulsen 2013).
Why it is important to do this review
Corticosteroids are used commonly in palliative care practice, espe-
cially for patients with advanced malignant disease, for a variety of
symptom control indications including pain, nausea, mood eleva-
tion, anorexia and fatigue (Farr 1990; Hardy 2001; Riechelmann
2007). This is despite the fact that steroids are associated with
significant side effects, especially following long-term use (Hanks
2009). There is little objective evidence in the literature to sup-
port the use of corticosteroids for symptom control, and concerns
have been raised about the ‘uncontrolled’ use of steroids in can-
cer patients (Gannon 2002). Patients who are started on steroids
in the palliative care setting are often not closely monitored, al-
lowing for the development of debilitating side effects, often in
the context of limited clinical benefit. Some of these side effects
include: proximal myopathy, oral candidiasis, the development of
osteoporosis, symptomatic hyperglycaemia, psychological distur-
bances, gastrointestinal irritation and increased susceptibility to
infections. For example, although steroids are frequently admin-
istered to assist with mood elevation, some studies have shown
that corticosteroid therapy may result in more disturbing side ef-
fects such as insomnia, delirium, depression, anxiety, and psychosis
(Vyvey 2010). There is a relevant gap in the body of knowledge, in
that most patients with cancer will be prescribed steroids at some
stage during their disease course.
O B J E C T I V E S
To assess the analgesic effects of corticosteroids for the manage-
ment of cancer-related pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomised controlled or prospective controlled trials. If
no randomised controlled trials are found, prospective controlled
studies will be examined.
Types of participants
Participants with cancer-related pain, aged 18 years and above.
Types of interventions
Any corticosteroid used to treat cancer-related pain.
All routes of drug administration will be considered.
Comparisons:
• placebo,
• no intervention,
• usual treatment or supportive care, or
• alternative non-pharmacological treatment for pain.
Types of outcome measures
Primary outcomes
Patient-reported pain intensity and pain relief using validated
scales (Visual Analogue Scale (VAS), Verbal Rating Scale (VRS),
Numerical Rating Scale (NRS)).
Secondary outcomes
• Adverse events.
• Quality of life scores.
• Patient satisfaction.
• Other relevant outcome measure e.g., cost-effectiveness
data.
Search methods for identification of studies
We will not apply language, date or publication status (published
in full, published as abstract, unpublished) restrictions to the
search.
Electronic searches
We will search the following databases:
1. The Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library)
2. MEDLINE (OVID) (1966 to present)
3. EMBASE (OVID) (1970 to present)
4. CINAHL (1982 to present)
5. Science Citation Index (Web of Science) (1899 to present)
6. Conference Proceedings Citation Index - Science (Web of
Science) (1990 to present).
The search strategy for MEDLINE (OVID) can be seen in
Appendix 1.
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Searching other resources
We will check the bibliographic references of relevant identified
studies in order to find additional trials not identified by the
electronic searches. We will also search www.Clinicaltrials.gov,
the metaRegister of Controlled Trials (mRCT www.controlled-
trials.com/mrct/), and the WHO International Clinical Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/) for ongo-
ing trials. We will contact authors of the included studies to ask
if they know of any other relevant studies. We will contact in-
vestigators/researchers, pharmaceutical companies, and interna-
tional funding agencies interested in this field to identify any fur-
ther studies. We will search the Internet using the Google scholar
search engine (www.googlescholar.com) with selected terms from
the above strategy, for any further unpublished or grey literature.
Data collection and analysis
Selection of studies
One of the authors (KR) will run the searches and collate the
search results. Two of the review authors will independently assess
the titles and abstracts of all the studies identified by the search
for potential inclusion. We will independently consider the full
records of all potentially-relevant studies for inclusion by apply-
ing the selection criteria outlined in the ‘Criteria for considering
studies for this review’ section. We will resolve potential disagree-
ments by discussion. If we cannot reach agreement, we will seek
the opinion of a third review author for a final judgment.
We plan to include a PRISMA study flow diagram in the full re-
view (Liberati 2009) to document the screening process, as rec-
ommended in Part 2, Section 11.2.1 of the Cochrane Handbook
(Higgins 2011).
Data extraction and management
Two review authors will independently extract data from the stud-
ies, using a piloted data extraction form. Data extracted will in-
clude information about the year of study, study design, number
of participants treated, participant demographic details, type of
cancer, drug and dosing regimen, study design (placebo or active
control) and methods, study duration and follow-up, outcome
measures (measurement of pain, pain scale), withdrawals and ad-
verse events.Wewill resolve potential disagreements by discussion.
If there are studies for which only a subgroup of the participants
meet the inclusion criteria for the current review, we will only ex-
tract data on this subgroup provided randomisation will not be
broken. If there are any missing data, we will attempt to contact
the authors of the original studies for clarification.
Assessment of risk of bias in included studies
Two of the authors will independently assess the risk of bias of
each of the included studies by using the ’Risk of bias’ assessment
method outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). For each study we will assess the
risk of bias for the following domains:
1. Selection bias (random sequence generation, allocation
concealment)
2. Performance bias (blinding of patients, blinding of treating
personnel)
3. Detection bias (blinding of outcome assessment)
4. Attrition bias (incomplete outcome data)
5. Selective reporting (reporting bias due to selective outcome
reporting)
6. Other sources of bias (bias due to problems not covered
elsewhere).
Measures of treatment effect
For dichotomous outcomes between groups, we will estimate and
compare the risk ratio (RR) using a 95% confidence interval (CI).
For continuous outcomes between groups, we will measure arith-
metic means and standard deviation (SD) and report the mean
difference (MD) with 95% CI. When an outcome was derived
with different instruments measuring the same construct, we will
use standardized mean difference (SMD) with 95% CIs.
For unwanted effects, we will calculate the numbers needed to
treat to harm (NNH) using dichotomous data to calculate risk
ratio (RR) with 95% confidence intervals (CI). We will use the
following terms to describe adverse outcomes in terms of harm or
prevention of harm:
• When significantly fewer adverse outcomes occur with
corticosteroids than with control (placebo or active) we will use
the term ’number needed to treat to prevent one event’ (NNTp).
• When significantly more adverse outcomes occur with
corticosteroids compared with control (placebo or active) we will
use the term ’number needed to harm or cause one event’
(NNH).
Unit of analysis issues
We will only include studies in which randomisation is by the
individual patient; this may include cross-over or n = 1 studies.
Dealing with missing data
In cases where data are missing, we will contact the authors to
request the missing data. Intention-to-treat (ITT) analysis will
be used. If there are missing participants or information, they
will be assigned to a zero improvement category where possible.
The method of assessing data processed from withdrawals will be
ascertained where possible. Where there are substantial numbers
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(> 10%) of participants missing from analyses, we will comment,
and plan to perform sensitivity analyses.
Assessment of heterogeneity
There may be an effect of differences between patients, environ-
ment (inpatient vs. outpatient) and outcome measures. We will
assess heterogeneity by using the I2 statistic. We will consider I
2 values above 50% to represent substantial heterogeneity in line
with Higgins 2011 and we will assess potential sources of hetero-
geneity through subgroup analyses.
Assessment of reporting biases
Wewill interpret the results of tests in the light of visual inspection
of the funnel plot. If there is evidence of small study effects, we
will consider publication bias as only one of a number of possible
explanations (Higgins 2011).
Data synthesis
We will enter the data extracted from the included studies into
Review Manager (RevMan 2012) which will be used for data syn-
thesis. Where appropriate, we will pool data for each dichotomous
outcome and calculate risk ratios with 95% confidence intervals
(CI) using the fixed-effect model, together with numbers needed
to treat to benefit (NNTs) with 95% CIs and, for adverse events,
numbers needed to treat to harm (NNHs) with 95% CIs .
Subgroup analysis and investigation of heterogeneity
Different aspects of the trials are likely to contribute heterogeneity
to the proposed main analyses. If there are sufficient data, we will
therefore perform subgroup analyses based on: type of corticos-
teroid, doses, route of administration, types of cancer, type of pain
(nociceptive, neuropathic, cancer-related, treatment-related), and
length of the trials.
Sensitivity analysis
If sufficient data are available, we will examine the robustness of
the meta-analyses by conducting sensitivity analyses using differ-
ent components of the ’Risk of bias’ assessment, particularly those
relating to whether allocation concealment and patient/assessor
blinding were adequate. We will conduct further sensitivity anal-
yses to examine the impact of missing data on the results if a large
proportion of the studies are at an ’unknown’ or ’high risk’ of at-
trition bias, and finally, sensitivity analyses will examine whether
publication status and trial size influence the results.
Summary of findings table
A Summary of findings table will be included as outlined in
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) (including a grade of the quality of evidence).
R E F E R E N C E S
Additional references
Baschant 2012
Baschant U, Tuckermann J. The role of the glucocorticoid
receptor in inflammation and immunity. Journal of Steroid
Biochemistry and Molecular Biology 2012;120:69–75.
Busillo 2013
Busillo JM, Cidlowski JA. The five Rs of glucocorticoid
action during inflammation: ready, reinforce, repress,
resolve, and restore. Trends in Endocrinology and Metabolism
2013;24(3):109–19.
Farr 1990
Farr WC. The use of corticosteroids for symptom
management in terminally ill patients. American Journal of
Hospice and Palliative Care 1990;7:41.
Foley 2011
Floey MK. How well is cancer pain treated?. Palliative
Medicine 2011;25(5):398–401.
Gannon 2002
Gannon C, McNamara P. A retrospective observation of
corticosteroid use at the end of life in a hospice. Journal of
Pain and Symptom Management 2002;24(3):328–34.
Hanks 2009
Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S,
Portenoy R (Editors). Oxford Textbook of Palliative Care.
4th Edition. Oxford Press, 2009.
Hardy 2001
Hardy J, Rees E, Ling J, Stone P, Burman R, Feuer D, et
al.A prospective survey of the use of dexamethasone on a
palliative care unit. Palliative Medicine 2001;15:3–8.
Higgins 2011
Higgins JPT, Altman DG (editors). Assessing risk of bias
in included studies. In: Higgins JPT, Green S editor(s).
Cochrane Handbook for Systematic Reviews of Interventions.
Version 5.1.0. The Cochrane Collaboration, Updated
March 2011.
Liberati 2009
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JPA, et al.The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration.
Annals of Internal Medicine 2009;151(4):W65–W94.
[DOI: 10.7326/0003-4819-151-4-200908180-00136]
4Corticosteroids for the management of cancer-related pain in adults (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Paulsen 2013
Paulsen O, Aass N, Kaasa S, Dale O. Do corticosteroids
provide analgesic effects in cancer patients? A systematic
review. Journal of Pain and Symptom Management 2013;46:
96–105.
RevMan 2012
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.2. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012.
Riechelmann 2007
Riechelmann RP, Krzyanowska MK, O’Carroll A,
Zimmermann C. Symptom and medication profiles among
cancer patients attending a palliative care clinic. Supportive
Care in Cancer 2007;15(12):1407–12.
Van den Beuken-van Everdingen 2007
Van den Beuken-van Everdingen MHJ, De Rijke JM,
Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence
of pain in patients with cancer: a systematic review of the
past 40 years. Annals of Oncology 2007;18:1437–49.
Vyvey 2010
Vyvey M. Steroids as pain relief adjuvants. Canadian Family
Physician 2010;56(12):1295–7.
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Adrenal Cortex Hormones/
2. (corticoid* or corticosteroid* or glucocorticoid*).tw.
3. (adrenal adj2 hormone*).tw.
4. Betamethasone/
5. betamethasone.tw.
6. Fludrocortisone/
7. fludrocortisone.tw.
8. Cortisone/
9. (cortisone acetate or cortisone).tw.
10. deflazacort.tw.
11. Dexamethasone/
12. dexamethasone.tw.
13. Hydrocortisone/
14. hydrocortisone.tw.
15. Methylprednisolone/
16. methylprednisolone.tw.
17. Prednisolone/
18. prednisolone.tw.
19. Triamcinolone/
20. triamcinolone.tw.
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. exp Pain/
23. pain.tw.
24. Pain Measurement/
25. exp Analgesics/
26. exp Analgesia/
27. “analges*”.tw.
28. (quality adj2 life).tw.
29. quality of life/
30. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. malignant.tw.
32. malignancy.tw.
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33. “tumor*”.tw.
34. “tumour*”.tw.
35. “cancer*”.tw.
36. “carcinoma*”.tw.
37. exp Neoplasms/
38. 31 or 32 or 33 or 34 or 35 or 36 or 37
39. 21 and 30 and 38
40. randomized controlled trial.pt.
41. controlled clinical trial.pt.
42. randomized.ab.
43. randomised.ab.
44. placebo.ab.
45. drug therapy.fs.
46. randomly.ab.
47. trial.ab.
48. groups.ab.
49. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
50. exp animals/ not humans.sh.
51. 49 not 50
52. 39 and 51
C O N T R I B U T I O N S O F A U T H O R S
All authors initiated and designed the study and drafted the protocol. All authors will extract the data and conduct ’Risk of bias’
assessment.
PG will supervise the statistical analysis, comment on and revise the review and will check the data extraction and arbitrate in the event
of disagreement between other authors.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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